Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe aortic stenosis (AS). Randomized studies have shown the benefits of TAVR for treating inoperable patients, as well as high and intermediate risk patients. The NOTION (Nordic Aortic Valve Intervention Trial) randomized patients with low risk severe AS to TAVR or SAVR (surgical<a href="https://solaci.org/en/2024/03/22/notion-trial-10-year-outcomes-tavr-vs-savr-in-low-risk-patients/" title="Read more" >...</a>
Guidewire Pacing and Pressure Assessment in TAVR: The SAFE-TAVI Study
Currently, the number of transcatheter aortic valve replacement (TAVR) procedures is increasing as it expands towards a lower-risk younger population. Therefore, continuous technological advancement is imperative to reduce post-procedural complications. The Food and Drug Administration (FDA) has approved the SavyWire, a preformed 0.035-gauge guidewire that can perform three essential functions: 1) it facilitates prosthesis transportation<a href="https://solaci.org/en/2024/03/20/guidewire-pacing-and-pressure-assessment-in-tavr-the-safe-tavi-study/" title="Read more" >...</a>
TENDER Study, Evolution at One Year
The use of transcatheter mitral valve intervention for the treatment of mitral valve regurgitation (MR) continues to evolve; at present guidelines only recommend it for inoperable or high surgical risk patients. So far, many devices have been assessed, some of which have shown promising results, but only for poor surgical candidates. Researchers looked into the<a href="https://solaci.org/en/2024/03/15/tender-study-evolution-at-one-year/" title="Read more" >...</a>
Use of Transjugular Echocardiography in TAVR
TAVR is a well-established course of treatment, increasingly indicated in lower risk populations. However, one of the challenges associated with self-expanding TAVR, compared against balloon expandable TAVR and SAVR, is the frequent need for definite permanent pacemaker implantation (PPI). High implantation, also known as cusp overlapping (COT), has been shown to reduce the need for<a href="https://solaci.org/en/2024/03/06/use-of-transjugular-echocardiography-in-tavr/" title="Read more" >...</a>
TAVR in Low Risk Patients: 10 Year Evolution
The Treatment of severe aortic stenosis has experienced a significant revolution with TAVR, especially in high and intermediate risk patients, and it is now extending to low risk patients. In the US, nearly half of patients under 64 are being treated with TAVR. One of the fundamental questions that still remains unanswered revolves around device<a href="https://solaci.org/en/2024/02/14/tavr-in-low-risk-patients-10-year-evolution/" title="Read more" >...</a>
Left Atrial Appendage Closure and Concomitant Transcatheter Intervention: Can We?
Several scientific societies support performing left atrial appendage occlusion (LAAO) as a stand-alone procedure, even though it is often associated to other cardiomyopathies requiring transcatheter intervention. Though still controversial, combining LAAO and any other cardiac intervention might reduce hospitalizations, as well as the need for additional punctures, anesthesia, red tape, a longer stay and higher<a href="https://solaci.org/en/2024/02/06/left-atrial-appendage-closure-and-concomitant-transcatheter-intervention-can-we/" title="Read more" >...</a>
Benefit of Cusp overlap method for self‐expanding transcatheter aortic valves
The need for permanent pacemaker implantation (PPM) continues to be one of the main challenges in TAVR, especially with self-expanding valves, with a pacemaker implantation rate that varies between 17.5% and 30% in large randomized studies, vs. 4% to 6.5% with self-expanding valves. Therefore, in an attempt to prevent the need for PPM implantation, the<a href="https://solaci.org/en/2024/02/02/benefit-of-cusp-overlap-method-for-self%e2%80%90expanding-transcatheter-aortic-valves/" title="Read more" >...</a>
Does Post-Dilation in TAVR Affect its Long-Term Outcomes?
Transcatheter aortic valve replacement (TAVR) has widely demonstrated its significant benefits, both in high-risk and inoperable patients, as well as in those with intermediate and low risk. While paravalvular regurgitation has been a challenge, its management has improved with operator experience and a deeper understanding of CT angiographies. However, in cases of regurgitation, elevated gradient,<a href="https://solaci.org/en/2024/02/01/does-post-dilation-in-tavr-affect-its-long-term-outcomes/" title="Read more" >...</a>
TricValve: 12-Month Evolution
Tricuspid regurgitation has become increasingly common, and current pharmacological treatment options are limited. In turn, surgery, which is a complex alternative, carries considerable rates of complications and mortality. In response to this issue, various percutaneous systems are being developed, such as edge-to-edge treatment, percutaneous annuloplasty, and caval valve implantation (CAVI), among others. In the analysis<a href="https://solaci.org/en/2024/01/18/tricvalve-12-month-evolution/" title="Read more" >...</a>
Carotid Stenosis and TAVR
Aortic Stenosis affects over 5% of the population over 65. Even though TAVR has advanced in the treatment of this disease, many patients present carotid aortic stenosis (CAS), which involves additional surgical risk. This risk has not been thoroughly assessed in the context of TAVR. A meta-analysis was carried out including 5 observational studies with<a href="https://solaci.org/en/2024/01/12/carotid-stenosis-and-tavr/" title="Read more" >...</a>